As US President Donald Trump announced pause on tariffs for 90 days for trade negotiations, India should avoid signing a comprehensive Free Trade Agreement (FTA) with the United States, as it may require India to make harmful trade-offs, suggests Global Trade Research Initiative (GTRI).
Asian stock markets surged on Thursday after US President Donald Trump announced a 90-day pause on tariffs for 75 countries, including India. This decision brought some relief to global investors amid rising trade tensions.
US President Donald Trump on Wednesday (local time) signed the commission for former Arkansas Governor Mike Huckabee to assume office as the United States Ambassador to Israel following his confirmation by the US Senate earlier in the day. He was confirmed by a vote of 53-46 in the Senate
US President Donald Trump on Wednesday (local time) defended his decision to raise tariffs on China to 125 per cent, stating, "somebody had to do it." The President, during his meeting with Roger Penske's NASCAR, INDY, and IMSA Champions at the White House, emphasised that no other US lea
The US Secretary of the Treasury highlighted the success of US President Trump's negotiating strategy, which he said has brought over 75 countries forward to engage in trade talks.
Amid the ongoing tariff war between the US and China that had been rattling the global markets, US President Donald Trump on Wednesday (local time) announced an immediate increase in tariffs on China to 125 per cent.
The Ministry of External Affairs (MEA) on Wednesday addressed the ongoing trade discussions with the United States, with spokesperson Randhir Jaiswal highlighting the efforts towards a mutually beneficial trade agreement.
External Affairs Minister (EAM) S Jaishankar spoke about the impact of the recent set of tariffs introduced by the US on countries across the world. He saw a silver lining and said that this would further boost the trade talks in place with the US. Jaishankar made the remarks at the Risin
Indian generic drug manufacturers play a significant role in the U.S. healthcare system, supplying nearly 40 percent of the generic drugs imported into the country.